<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT2014030516858N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2014-04-01</date_registration>
      <primary_sponsor>Mazandaran University of Medical Sciences</primary_sponsor>
      <public_title>Compare Two Different Methods of Ovarian Stimulation On Outcome of In Vitro Fertilization (IVF)</public_title>
      <acronym></acronym>
      <scientific_title>The Evaluation of The Effects of Mild Ovarian Stimulation on IVF(in vitro fertilization ) Results In Comparison With Conventional Method ,The Infertility Center Hospital Patients,2012-2013</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2012-03-20</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>204</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/15654</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Infertility.</hc_freetext>
      <i_freetext>Intervention 1: Control Group(group active control or standard )  :The Cases in This Group Will Be Treated with Conventional Ovarian Stimulation .They  Desensitized  with  OCP  ,Sarting on 3th Cycle Day.in  Menstrual Cycle 21th Day, They  Were Injected  0.5  cc  Superfact  (GNRH-a),(S.C)  and  in  3th   Day  of  Menstrual &#13;
Bleeding The Dosage Was Changed Into The   0.25 cc (S.C) In The Patients.  &#13;
Ovarian Stimulation  Was Started  With  150–225 IU  Recombinant FSH (r_FSH) S.C. Intervention 2: Patients  in  Group With New Treatment(mild Ovary Stimulation)   Were  Stimulated  Clomiphene  Citrate 100 mg From Cycle Day  Three Through  Seven  and  Continuous  Gonadotropin Stimulation With Of r_FSH 75 IU  Daily From Cycle Day 5.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan></results_IPD_plan>
      <results_IPD_description></results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Dr Sepideh Peyvandi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Emam Khomaini Hospital, Amir Mazandarani Street , SARI,MAZANDARAN ,IRAN</address>
        <city>sari</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>12345</zip>
        <telephone>+98 15 1226 1700</telephone>
        <email>drspeynadi@mazums.ac.irhoora_2243@yahoo.comasdvsdpda@yahoo.com</email>
        <affiliation>Mazandaran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr Sepideh Peyvandi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Emam Khomaini Hospital, Amir Mazandarani Street , SARI ,MAZANDARAN , IRAN</address>
        <city>sari</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip></zip>
        <telephone>+1 512261700</telephone>
        <email>drspeyvandi@mazums.ac.irhoora_2243@yahoo.comasdvsdpda@yahoo.com</email>
        <affiliation>Mazandaran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Inclusion criteria: female patient age 18–35 years; presence of a regular&#13;
; proven ovulatory menstruation cycle with a length of 26–35 days, more that 5 million sperm in SA(semen analysis);body mass index (BMI)&#13;
of 18–30 kg/m ; ﬁrst IVF attempt  .&#13;
Exclusion criteria:established systemic disease ;ovary and  Uterus abnormalities;repeated abortions.</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>35 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria></exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>N97</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Female Infertility</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Control Group(group active control or standard )  :The Cases in This Group Will Be Treated with Conventional Ovarian Stimulation .They  Desensitized  with  OCP  ,Sarting on 3th Cycle Day.in  Menstrual Cycle 21th Day, They  Were Injected  0.5  cc  Superfact  (GNRH-a),(S.C)  and  in  3th   Day  of  Menstrual &#13;
Bleeding The Dosage Was Changed Into The   0.25 cc (S.C) In The Patients.  &#13;
Ovarian Stimulation  Was Started  With  150–225 IU  Recombinant FSH (r_FSH) S.C.</i_keyword>
      <i_keyword>Patients  in  Group With New Treatment(mild Ovary Stimulation)   Were  Stimulated  Clomiphene  Citrate 100 mg From Cycle Day  Three Through  Seven  and  Continuous  Gonadotropin Stimulation With Of r_FSH 75 IU  Daily From Cycle Day 5.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Increase Endometrial Thickness. Timepoint: 2 Days After HCG Injection. Method of measurement: Sonography.</prim_outcome>
      <prim_outcome>Increase Implantation. Timepoint: 3 week. Method of measurement: Lab Test.</prim_outcome>
      <prim_outcome>Increase Chemical Pregnancy. Timepoint: 12 Day. Method of measurement: ß-hCG.</prim_outcome>
      <prim_outcome>Increase Clinical Pregnancy. Timepoint: 3 week. Method of measurement: Sonography.</prim_outcome>
      <prim_outcome>Decrease  Treatment Cost. Timepoint: Delivery Time. Method of measurement: Counting-RIALs.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Decrease OHSS Syndrom. Timepoint: Delivery Time. Method of measurement: Counting.</sec_outcome>
      <sec_outcome>Decrease of Multiple Pregnancy. Timepoint: Delivery Time. Method of measurement: Counting.</sec_outcome>
      <sec_outcome>Increase Of Follicular Number. Timepoint: 8 Day. Method of measurement: Counting.</sec_outcome>
      <sec_outcome>Increase Of Ovoocyt Number. Timepoint: 10 Days. Method of measurement: Counting.</sec_outcome>
      <sec_outcome>Increase Of Embryo Freez. Timepoint: 3week. Method of measurement: Counting.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Mazandaran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2012-11-07</approval_date>
        <contact_name>Mazandaran University of Medical Sciences</contact_name>
        <contact_address>Payambar Aazam Department, 18th kilometer of Sea Roud, SARI , MAZANDARAN , IRAN Sari  Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
